Clinical Trial

Dapagliflozin Delays the Loss of Renal Function in Peritoneal Dialysis Patients

Name: Dapagliflozin Delays the Loss of Renal Function in Peritoneal Dialysis Patients — clinical trial record (NCT06398977)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting

View on ClinicalTrials.gov →

Record status

This record was last updated May 3, 2024 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.

Summary

This study aims to explore the role of dagliflozin in preserving the residual renal function(RRF) in peritoneal dialysis (PD) patients.

Trial Details

NCT Number	NCT06398977
Lead Sponsor	Sichuan Academy of Medical Sciences
Conditions	Peritoneal Dialysis Complication, Renal Function Aggravated, Sodium-glucose Co-transporter-2 Inhibitors
Enrollment	70 participants
Start Date	2024-03-11
Primary Completion	2026-06-30 (estimated)
Study Completion	2026-12-31 (estimated)
Updated on ClinicalTrials.gov	2024-05-03